Photo taken from Day One Biopharmaceuticals/X
Apr 28, 2024, 13:23
Sam Blackman: US FDA approved the first targeted medicine for the treatment of patients with relapsed or refractory pediatric low-grade glioma
Sam Blackman, Co-founder and Chief Medical Officer of Day One Biopharmaceuticals, shared a post by Day One Biopharmaceuticals, on X:
“Proud of the hard work from the Day One Biopharmaceuticals teams and the broader pediatric oncology community to make this achievement possible! We did it!”
Quoting Day One Biopharmaceuticals‘s post:
“We are proud to share the accelerated approval by the US FDA of the first targeted medicine for the treatment of patients with relapsed or refractory pediatric low-grade glioma (pLGG) with a BRAF fusion or rearrangement, or BRAF V600 mutation. ”
Source: Sam Blackman/X and Day One Biopharmaceuticals/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21